

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III EMILIA trial of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib for advanced HER2-positive breast cancer previously treated with trastuzumab and a taxane demonstrated a significant improvement in _____.

 - a. Progression-free survival
 - b. Overall survival
 - c. Overall response rate
 - d. Both a and c
 - e. All of the above
2. Weekly nanoparticle albumin-bound (*nab*) paclitaxel was superior to weekly paclitaxel in terms of progression-free and overall survival as demonstrated by the CALGB 40502 Phase III trial of first-line therapy for locally recurrent or metastatic breast cancer.

 - a. True
 - b. False
3. Enzalutamide demonstrated a significant improvement in _____ after chemotherapy when compared to placebo in the interim analysis of the Phase III AFFIRM trial in patients with castration-resistant prostate cancer.

 - a. Overall survival
 - b. Progression-free survival
 - c. Time to PSA progression
 - d. All of the above
 - e. None of the above
4. Results of the Phase I/II weekly dosing study of the oral proteasome inhibitor MLN9708 combined with lenalidomide and dexamethasone did not demonstrate a favorable overall response rate in patients with newly diagnosed multiple myeloma.

 - a. True
 - b. False
5. Improvements in _____ were reported with the combination arm in a randomized Phase II trial comparing monotherapy with the BRAF inhibitor dabrafenib versus dabrafenib in combination with the MEK1/2 inhibitor trametinib in patients with BRAF-V600 mutation-positive metastatic melanoma.

 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
6. The Phase III REGARD trial comparing ramucirumab and best supportive care (BSC) to placebo and BSC met its primary endpoint of improved overall survival and also demonstrated prolonged progression-free survival.

 - a. True
 - b. False
7. The PointBreak trial of pemetrexed (pem) with carboplatin (Cb) and bevacizumab (bev) → maintenance pem/ bev versus paclitaxel/Cb/bev → maintenance bev showed a significant improvement in overall survival with pem/Cb/bev → maintenance pem/bev.

 - a. True
 - b. False
8. Grade 3/4 adverse events associated with aflibercept in the VELOUR trial included the following:

 - a. Fatigue
 - b. Diarrhea
 - c. Hypertension
 - d. Pulmonary embolism
 - e. All of the above

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. For patients with CML, mutational analysis and monitoring is recommended in the following scenarios:

- a. Loss of complete cytogenetic response
- b. Late hematologic relapse
- c. Either a or b
- d. Neither a nor b

10. The follow-up of the COMFORT I trial of JAK inhibition with ruxotinib versus placebo for patients with myelofibrosis demonstrated significant improvements in _____.

- a. Overall survival
- b. Splenomegaly
- c. Quality of life
- d. All of the above